These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 17902246)
21. Human versus HIV: round 2 defeat in AIDS vaccine development. Lu S Expert Rev Vaccines; 2008 Mar; 7(2):151-3. PubMed ID: 18324884 [No Abstract] [Full Text] [Related]
22. HIV "new strain" story: for more information. James JS AIDS Treat News; 2005 Jan; (409):3. PubMed ID: 15791711 [TBL] [Abstract][Full Text] [Related]
23. Genetic and immune correlates of the HIV infection and vaccine-induced immunity. Foreword. Füst G Vaccine; 2008 Jun; 26(24):2949-50. PubMed ID: 18321613 [No Abstract] [Full Text] [Related]
24. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment. Shi V; Tridane A; Kuang Y J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195 [TBL] [Abstract][Full Text] [Related]
25. Genome-wide association scan in HIV-1-infected individuals identifying variants influencing disease course. van Manen D; Delaneau O; Kootstra NA; Boeser-Nunnink BD; Limou S; Bol SM; Burger JA; Zwinderman AH; Moerland PD; van 't Slot R; Zagury JF; van 't Wout AB; Schuitemaker H PLoS One; 2011; 6(7):e22208. PubMed ID: 21811574 [TBL] [Abstract][Full Text] [Related]
26. First rat HIV model. O'Neill P Trends Mol Med; 2001 Oct; 7(10):434. PubMed ID: 11597515 [No Abstract] [Full Text] [Related]
27. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. Ensoli B; Fiorelli V; Ensoli F; Lazzarin A; Visintini R; Narciso P; Di Carlo A; Monini P; Magnani M; Garaci E AIDS; 2008 Oct; 22(16):2207-9. PubMed ID: 18832884 [TBL] [Abstract][Full Text] [Related]
29. Molecular and cellular interactions of HIV-1/HTLV coinfection and impact on AIDS progression. Casoli C; Pilotti E; Bertazzoni U AIDS Rev; 2007; 9(3):140-9. PubMed ID: 17982939 [TBL] [Abstract][Full Text] [Related]
31. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217 [TBL] [Abstract][Full Text] [Related]
32. On modeling the effects of T-cell vaccines on HIV acquisition and disease. Wick WD Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425 [TBL] [Abstract][Full Text] [Related]
33. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Waters L; Mandalia S; Randell P; Wildfire A; Gazzard B; Moyle G Clin Infect Dis; 2008 May; 46(10):1617-23. PubMed ID: 18419499 [TBL] [Abstract][Full Text] [Related]
34. HIV-1 subtype as a determinant of disease progression. Kuritzkes DR J Infect Dis; 2008 Mar; 197(5):638-9. PubMed ID: 18266606 [No Abstract] [Full Text] [Related]
35. Biological properties of HIV-1 subtype B' isolates from infected Chinese blood donors at different disease stages. Chen Y; Shen C; Wu H; Caruso L; Ratner D; Rodriguez M; Chen X; Gupta P Virology; 2009 Feb; 384(1):161-8. PubMed ID: 19058828 [TBL] [Abstract][Full Text] [Related]
36. Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? Goujard C; Chaix ML; Lambotte O; Deveau C; Sinet M; Guergnon J; Courgnaud V; Rouzioux C; Delfraissy JF; Venet A; Meyer L; Clin Infect Dis; 2009 Sep; 49(6):982-6. PubMed ID: 19681706 [TBL] [Abstract][Full Text] [Related]